Optimising RAASi Management in Cardiorenal Patients: An Expert Roundtable
Join cardiologists Dr Shelley Zieroth (University of Manitoba, Winnipeg, CA) and Dr Aaron Wong (Princess of Wales Hospital, Wales, UK) and nephrologists Dr Andrew Frankel (Imperial College Healthcare NHS Trust, London, UK), and Dr Manish Sood (University of Ottawa, CA) when they discuss the nuanced landscape of RAASi management in cardiorenal patients in this live roundtable.
In this discussion, our expert faculty consider approaches to optimal RAASi dosing and strategies to improve patient outcomes. The programme integrates data-driven insights, established guidelines, and expert consensus, offering participants a holistic understanding of RAASi management.
A case study will highlight how to overcome barriers to optimal guideline-directed medical therapy and panel discussion will bridge theory and real-world application, providing you with actionable tools to implement optimal practices in your daily clinical pursuits.
Register today to secure your place!
In collaboration with Kidney Disease: Improving Global Outcomes (KDIGO) group.
KDIGO is a global organisation developing and implementing evidence-based clinical practice guidelines in kidney disease. It is an independent, volunteer-led, self-managed foundation incorporated in Belgium and accountable to the public and the patients it serves.
KDIGO has a network of dedicated volunteers from around the world who promote awareness, dissemination, adoption, and clinical integration of KDIGO Guidelines both globally and in their respective countries or regions.
KDIGO guidelines translate scientific advances into useful and practical clinical practice recommendations and observations.
This programme is supported by an unrestricted educational grant from AstraZeneca.
RAASi Management in CKD/HF: What We Should Be Doing
RAASi Management in CKD/HF: What Is Happening in the Real World?
Panel Discussion and Audience Q&A
- Describe the prevalence and clinical impact of sub-optimal RAASi use in cardiorenal patients
- Recall key messages from current guidelines, consensus and clinical evidence for optimised RAASi management in cardiorenal patients
- Describe common barriers to optimised RAASi management strategies
- Use expert-led guidance to develop a practical approach to overcoming the barriers to RAASi use and the reinitiation/up-titration of therapy
- Heart Failure Specialists
- Other Allied HCPs
Dr Aaron Wong is consultant cardiologist and general physician at the Princess of Wales Hospital, Wales, UK and is also an honorary lecturer at the University of Cardiff, UK.
His research interests include heart failure and cardiometabolic disease.
Dr Andrew Frankel has been working as a consultant nephrologist at Imperial College Healthcare NHS trust since 1995. He has experience in managing all aspects of kidney disease but has a particular interest in relation to the management of diabetes in the context of kidney disease. Over the years he has maintained a significant research interest in relation to diabetes and kidney, both in terms of how diabetes affects the kidneys leading to deterioration in kidney function, but also in relation to how the presence of kidney disease influences the management of diabetes. Because of this experience, Dr Frankel has played a significant role in the development of national guidelines on the management of diabetes in the context of kidney disease. He is a regular speaker both locally and nationally and indeed internationally in relation to matters pertaining to diabetes and the kidney.
In collaboration with colleagues within Imperial College and indeed both nationally and internationally, Dr Frankel has published research in relation to assessment of renal complications in patients with diabetes and obesity. He is active in clinical research and maintains a number of ongoing research studies.
Dr Frankel has significant commitment to and experience in relation to training the next generation of doctors, having been the director Imperial’s Foundation School from its inception to 2010, London lead for Foundation Training and Postgraduate Dean for south London from 2013 and 2018.
Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St Boniface Hospital in Winnipeg, Canada. She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba.
She is involved in several heart failure clinical trials as a PI, National Lead or Executive Committee member. She is the Past President of the Canadian Heart Failure Society and Co-Chair of the Canadian Cardiovascular Society Heart Failure Guidelines. She is co-chair of Canada’s largest annual heart failure meeting, HF Update, and Past President of the Federation of Medical Women of Canada.
Dr Shelley Zieroth is an Editorial Board member of Cardiac Failure Review.
Dr Manish Sood is an Assistant Professor of Medicine at the University of Ottawa with cross appointment at the School of Epidemiology and Public Health, Scientist at the Ottawa Hospital Research Institute and the Institute for Clinical Evaluative Sciences, Deputy Editor- in- Chief and founder of the Canadian Journal of Kidney Health and Disease, and holds the Jindal Research Chair for the Prevention of Kidney Disease.
He completed his undergraduate (BSc) at Carleton and Lancaster University (UK) followed by medical school, internal medicine and nephrology residency training at the University of Toronto. He began his career as a clinical nephrologist at the St Boniface Hospital in Winnipeg, Manitoba, gradually developing an interest in research and clinical epidemiology and in 2013 became a clinician scientist. He completed his Masters in Science in Epidemiology at the University of Ottawa.